{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-277328","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2022-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.433534+00:00","generated_at":"2026-06-22T07:15:16.607710+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioAtla reports 36% ORR in NSCLC and meets Go criteria in multiple sarcoma subtypes for BA3011","bullets":["NSCLC Phase 2 Part 1: ORR 36% (5/14), 42% in non-squamous (5/12); 1 CR and 4 PRs.","Sarcoma: Go criteria met for UPS, osteosarcoma, liposarcoma, and synovial sarcoma into Part 2.","UPS (Phase 1&2, n=10): ORR 50% (4/8 evaluable), 3-month PFS rate 50%, median PFS 6.8 months.","Osteosarcoma (n=6): 3-month PFS rate 66.7%; liposarcoma (n=6): 66.7%; synovial sarcoma (n=5): 54%.","FDA supportive of proposed registrational Part 2 study in UPS (n=80, primary endpoint ORR); enrollment expected by year-end 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-277328","json":"https://secwatch.observer/filing/0001193125-22-277328.json","markdown":"https://secwatch.observer/filing/0001193125-22-277328.md","text":"https://secwatch.observer/filing/0001193125-22-277328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000119312522277328/0001193125-22-277328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000119312522277328/d416713d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:15:16.607710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}